Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma

Ann Hematol. 2019 Jun;98(6):1505-1506. doi: 10.1007/s00277-018-3541-0. Epub 2018 Nov 9.

Authors

Alessandra Serrao¹, Martina Canichella¹, Maria Lucia De Luca¹, Germana Tartaglia¹, Giorgia Annechini¹, Gianna Maria D'Elia¹, Alessandro Pulsoni²

Affiliations

¹ Department of Cellular Biotecnologies and Hemathology, Sapienza University of Rome, Via Benevento 6, 00161, Rome, Italy.
² Department of Cellular Biotecnologies and Hemathology, Sapienza University of Rome, Via Benevento 6, 00161, Rome, Italy. pulsoni@bce.uniroma1.it.

PMID: 30413900
DOI: 10.1007/s00277-018-3541-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-HIV Agents / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Brentuximab Vedotin
CD4 Lymphocyte Count
Drug Resistance, Neoplasm
Hodgkin Disease / drug therapy*
Hodgkin Disease / therapy
Humans
Immunoconjugates / administration & dosage
Karnofsky Performance Status
Lymphoma, AIDS-Related / drug therapy*
Male
Middle Aged
Nivolumab / therapeutic use*
Peripheral Blood Stem Cell Transplantation
Transplantation Conditioning
Transplantation, Autologous
Viral Load

Substances

Anti-HIV Agents
Antineoplastic Agents, Immunological
Immunoconjugates
Nivolumab
Brentuximab Vedotin